FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379143707> ?p ?o ?g. }

• W4379143707 endingPage "B001" @default.
• W4379143707 startingPage "B001" @default.
• W4379143707 abstract "Abstract Bladder, colon, gastric, prostate, and uterine cancers originate from the organ’s epithelium, and each organ is surrounded by smooth muscle. In prostate cancer, organ-confined tumors, without extracapsular extension (ECE) through muscle, have a 5-year survival rate of 99% compared to 31% for metastatic disease. Previously, we modeled tumor cluster ECE and reported that a CRISPR-Cas9 integrin mutation (α6AA) blocked ECE by switching from a cell-ECM to a cell-cell biophysical phenotype. Since tumors are mosaics and migrate as heterogeneous drug-resistant populations, we tested the functional heterogeneity of the two biophysical cell phenotypes in ECE. Experimental procedures included the in vivo mouse xenograft model of ECE as a functional endpoint of muscle invasion, the MTT assay for cell survival, and using electric cell impedance sensing (ECIS) measurements to directly compare the biophysical properties of tumor cells expressing the invasion permissive α6WT integrin, cells expressing only the α6AA mutation, or a mixed population expressing both integrin types. The α6AA integrin mutation or α6KO knockout produced cells unable to invade into and through the smooth muscle of the mouse as compared to the α6WT integrin cells, as previously reported by us. The new unpublished results are that cell adhesion mediated drug resistance was detected in the α6AA population since their LD50 to Bortezomib, Gemcitabine, and Taxotere was shifted to 33.71nM, 64.66nM, and 5.77nM respectively from 16.29nM, 31.74nM, and 3.52nM in the α6WT cells as measured by MTT assay at 72 hours of incubation. In contrast, the α6AA cells were sensitized to the NAMPT inhibitor, FK866, with LD50 shifting from 27.46nM in α6WT to 7.354nM in the α6AA cells. A mixture of α6AA and α6WT cells allowed invasion into and through the muscle in the mouse of the mutant α6AA integrin cells that could not invade on their own. Examining the live cellular biophysical parameters revealed that the integrin mutation produced a 4-fold increase in cell-cell resistance (400Hz measurement) and a 12-fold recovery time delay in re-establishing a cell-cell resistance monolayer after wounding, with response complexity decreased two-fold. Cell-ECM resistance (40,000Hz measurement) in α6AA versus α6WT population was 1.5-fold decreased with a 6-fold recovery time delay in the cell-ECM resistance monolayer and response complexity decreased 2-fold. A heterogenous population containing up to a 4:1 proportion of α6AA to α6WT cells synergistically delayed cell-cell recovery time of the wounded monolayer up to 6-fold compared to the α6WT cells. Conversely, recovery of the wounded cell-ECM resistance monolayer with 1:1 or 4:1 mixture of α6AA cell only delayed recovery time by 1.5–1.7-fold. Taken together, these data suggest that a heterogenous tumor population provides functional advantages for drug-resistant tumor cells to invade and traverse the muscle barrier. Current work is ongoing to optimize the drug combinations to eliminate both phenotypes in the invasive tumor network and prevent ECE. Citation Format: Kendra D. Marr, Jaime M.C. Gard, William L. Harryman, Elijah J. Keeswood, Allan I. Paxson, Charles Wolgemuth, Lori A. Hazlehurst, Raymond B. Nagle, Anne E. Cress. Heterogeneity of cancer network biophysical phenotypes is required for tumor muscle invasion in vivo [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr B001." @default.
• W4379143707 created "2023-06-03" @default.
• W4379143707 creator A5000722084 @default.
• W4379143707 creator A5019184392 @default.
• W4379143707 creator A5024357800 @default.
• W4379143707 creator A5037551572 @default.
• W4379143707 creator A5054463097 @default.
• W4379143707 creator A5080838230 @default.
• W4379143707 creator A5080916822 @default.
• W4379143707 creator A5092074049 @default.
• W4379143707 creator A5092074050 @default.
• W4379143707 date "2023-06-02" @default.
• W4379143707 modified "2023-09-27" @default.
• W4379143707 title "Abstract B001: Heterogeneity of cancer network biophysical phenotypes is required for tumor muscle invasion <i>in vivo</i>" @default.
• W4379143707 doi "https://doi.org/10.1158/1538-7445.prca2023-b001" @default.
• W4379143707 hasPublicationYear "2023" @default.
• W4379143707 type Work @default.
• W4379143707 citedByCount "0" @default.
• W4379143707 crossrefType "journal-article" @default.
• W4379143707 hasAuthorship W4379143707A5000722084 @default.
• W4379143707 hasAuthorship W4379143707A5019184392 @default.
• W4379143707 hasAuthorship W4379143707A5024357800 @default.
• W4379143707 hasAuthorship W4379143707A5037551572 @default.
• W4379143707 hasAuthorship W4379143707A5054463097 @default.
• W4379143707 hasAuthorship W4379143707A5080838230 @default.
• W4379143707 hasAuthorship W4379143707A5080916822 @default.
• W4379143707 hasAuthorship W4379143707A5092074049 @default.
• W4379143707 hasAuthorship W4379143707A5092074050 @default.
• W4379143707 hasConcept C121608353 @default.
• W4379143707 hasConcept C142724271 @default.
• W4379143707 hasConcept C1491633281 @default.
• W4379143707 hasConcept C150903083 @default.
• W4379143707 hasConcept C195687474 @default.
• W4379143707 hasConcept C203014093 @default.
• W4379143707 hasConcept C207001950 @default.
• W4379143707 hasConcept C2776364478 @default.
• W4379143707 hasConcept C2777478702 @default.
• W4379143707 hasConcept C2780192828 @default.
• W4379143707 hasConcept C2908647359 @default.
• W4379143707 hasConcept C502942594 @default.
• W4379143707 hasConcept C54355233 @default.
• W4379143707 hasConcept C71924100 @default.
• W4379143707 hasConcept C86803240 @default.
• W4379143707 hasConcept C96232424 @default.
• W4379143707 hasConcept C99454951 @default.
• W4379143707 hasConceptScore W4379143707C121608353 @default.
• W4379143707 hasConceptScore W4379143707C142724271 @default.
• W4379143707 hasConceptScore W4379143707C1491633281 @default.
• W4379143707 hasConceptScore W4379143707C150903083 @default.
• W4379143707 hasConceptScore W4379143707C195687474 @default.
• W4379143707 hasConceptScore W4379143707C203014093 @default.
• W4379143707 hasConceptScore W4379143707C207001950 @default.
• W4379143707 hasConceptScore W4379143707C2776364478 @default.
• W4379143707 hasConceptScore W4379143707C2777478702 @default.
• W4379143707 hasConceptScore W4379143707C2780192828 @default.
• W4379143707 hasConceptScore W4379143707C2908647359 @default.
• W4379143707 hasConceptScore W4379143707C502942594 @default.
• W4379143707 hasConceptScore W4379143707C54355233 @default.
• W4379143707 hasConceptScore W4379143707C71924100 @default.
• W4379143707 hasConceptScore W4379143707C86803240 @default.
• W4379143707 hasConceptScore W4379143707C96232424 @default.
• W4379143707 hasConceptScore W4379143707C99454951 @default.
• W4379143707 hasIssue "11_Supplement" @default.
• W4379143707 hasLocation W43791437071 @default.
• W4379143707 hasOpenAccess W4379143707 @default.
• W4379143707 hasPrimaryLocation W43791437071 @default.
• W4379143707 hasRelatedWork W2010684987 @default.
• W4379143707 hasRelatedWork W2045315430 @default.
• W4379143707 hasRelatedWork W2084874861 @default.
• W4379143707 hasRelatedWork W2146826997 @default.
• W4379143707 hasRelatedWork W2344637265 @default.
• W4379143707 hasRelatedWork W2511845891 @default.
• W4379143707 hasRelatedWork W2763585477 @default.
• W4379143707 hasRelatedWork W2809002819 @default.
• W4379143707 hasRelatedWork W3160990505 @default.
• W4379143707 hasRelatedWork W3126236615 @default.
• W4379143707 hasVolume "83" @default.
• W4379143707 isParatext "false" @default.
• W4379143707 isRetracted "false" @default.
• W4379143707 workType "article" @default.